Cinctive Capital Management LP Sells 46,792 Shares of Sanofi (NASDAQ:SNY)

Cinctive Capital Management LP reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 30.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,317 shares of the company’s stock after selling 46,792 shares during the quarter. Cinctive Capital Management LP’s holdings in Sanofi were worth $5,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SNY. Massachusetts Financial Services Co. MA lifted its stake in Sanofi by 4.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 155,078 shares of the company’s stock valued at $7,479,000 after acquiring an additional 7,123 shares during the period. Geode Capital Management LLC boosted its holdings in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company’s stock worth $12,427,000 after purchasing an additional 2,917 shares during the last quarter. Diametric Capital LP purchased a new stake in Sanofi in the fourth quarter worth approximately $214,000. National Bank of Canada FI grew its position in Sanofi by 2.0% in the 4th quarter. National Bank of Canada FI now owns 303,934 shares of the company’s stock worth $14,659,000 after purchasing an additional 6,089 shares during the period. Finally, HighPoint Advisor Group LLC raised its stake in Sanofi by 7.2% during the 4th quarter. HighPoint Advisor Group LLC now owns 8,985 shares of the company’s stock valued at $433,000 after buying an additional 601 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.7 %

SNY stock opened at $53.95 on Thursday. The business’s 50-day moving average price is $55.33 and its 200-day moving average price is $52.74. The stock has a market cap of $136.92 billion, a P/E ratio of 21.67, a PEG ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.